Zacks Research Upgrades AtriCure (NASDAQ:ATRC) to Strong-Buy

AtriCure (NASDAQ:ATRC) was upgraded by equities researchers at Zacks Research from a “hold” rating to a “strong-buy” rating in a note issued to investors on Wednesday, Zacks reports.

Several other equities analysts have also issued reports on ATRC. JPMorgan Chase & Co. lifted their price target on AtriCure from $36.00 to $62.00 and gave the stock a “neutral” rating in a research report on Wednesday. Citizens Jmp increased their price objective on shares of AtriCure from $52.00 to $68.00 and gave the company a “market outperform” rating in a research report on Wednesday, October 21st. Needham & Company LLC raised their price objective on shares of AtriCure from $64.00 to $70.00 and gave the company a “buy” rating in a research note on Wednesday. Raymond James Financial set a $52.00 price objective on shares of AtriCure in a research note on Tuesday, July 21st. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $70.00 target price (up from $60.00) on shares of AtriCure in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, AtriCure presently has a consensus rating of “Moderate Buy” and a consensus price target of $61.80.

AtriCure Stock Performance

AtriCure stock opened at $61.28 on Wednesday. AtriCure has a twelve month low of $25.36 and a twelve month high of $66.02. The company has a quick ratio of 3.19, a current ratio of 4.33 and a debt-to-equity ratio of 0.11. The company has a market capitalization of $3.12 billion, a P/E ratio of 204.27 and a beta of 1.23. The stock’s 50 day moving average is $56.62 and its 200 day moving average is $38.63.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings data on Tuesday, November 3rd. The medical device company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.23. AtriCure had a return on equity of 4.01% and a net margin of 2.52%. The business had revenue of $154.45 million during the quarter, compared to analysts’ expectations of $151.05 million. On average, equities research analysts predict that AtriCure will post 0.29 earnings per share for the current fiscal year.

Insider Buying and Selling at AtriCure

In other news, Director Regina E. Groves sold 5,313 shares of the business’s stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $54.22, for a total transaction of $288,070.86. Following the completion of the transaction, the director directly owned 34,546 shares of the company’s stock, valued at $1,873,084.12. The trade was a 13.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Salvatore Privitera sold 8,404 shares of the stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $65.00, for a total transaction of $546,260.00. Following the transaction, the insider owned 134,341 shares in the company, valued at approximately $8,732,165. This trade represents a 5.89% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 39,026 shares of company stock worth $2,172,263. Company insiders own 4.00% of the company’s stock.

Institutional Investors Weigh In On AtriCure

A number of hedge funds have recently added to or reduced their stakes in the stock. Harbor Investment Advisory LLC bought a new stake in AtriCure during the second quarter valued at approximately $40,000. Allworth Financial LP purchased a new stake in AtriCure during the second quarter valued at approximately $43,000. Fulcrum Asset Management LLP bought a new position in AtriCure in the third quarter worth approximately $92,000. Integrated Wealth Concepts LLC bought a new position in AtriCure in the second quarter worth approximately $46,000. Finally, Sterling Capital Management LLC grew its position in shares of AtriCure by 841.1% during the 3rd quarter. Sterling Capital Management LLC now owns 1,647 shares of the medical device company’s stock valued at $93,000 after acquiring an additional 1,472 shares during the period. 99.11% of the stock is currently owned by hedge funds and other institutional investors.

Key AtriCure News

Here are the key news stories impacting AtriCure this week:

• Positive Sentiment: Third-quarter adjusted earnings were $0.17 per share, ahead of the $0.06-per-share loss analysts expected, while revenue of $154.45 million also topped estimates. AtriCure raised its 2026 revenue guidance to $606 million–$610 million and projected adjusted EBITDA of $91 million–$94 million. AtriCure reports third-quarter results AtriCure outlook and study enrollment
• Positive Sentiment: Several analysts raised price targets following the results. Piper Sandler reiterated Overweight and raised its target to $70; Needham also set a $70 target, while Canaccord raised its target to $67 with a Buy rating. These revisions signal continued confidence in AtriCure’s growth prospects. Analysts raise forecasts Piper Sandler rating
• Neutral Sentiment: JPMorgan raised its target substantially, to $62, but maintained a Neutral rating—suggesting limited upside in its view. JPMorgan rating and target
• Negative Sentiment: A valuation-focused article questioned whether strong results and the higher outlook are already reflected in the stock, which could constrain further gains after its recent run-up. AtriCure valuation discussion
• Negative Sentiment: Insider Salvatore Privitera sold 8,404 shares for about $546,000. The sale was made under a pre-arranged Rule 10b5-1 plan, and he retained 134,341 shares, making the signal less concerning than an unplanned sale. SEC insider filing

About AtriCure

AtriCure, Inc is a medical device company that develops and sells products for the surgical treatment of atrial fibrillation (AFib) and related conditions. Its technologies are designed to support cardiac surgeons and electrophysiologists performing tissue ablation, left atrial appendage management and other procedures intended to restore or maintain normal heart rhythm.

The company’s product portfolio includes the AtriClip device, which is used to exclude the left atrial appendage, along with surgical ablation systems such as the Isolator Synergy clamps and cryoablation products.